Research programme: bispecific monoclonal antibodies - Innovent Biologics/Eli Lilly

Drug Profile

Research programme: bispecific monoclonal antibodies - Innovent Biologics/Eli Lilly

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Innovent Biologics
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 11 Oct 2015 Eli Lilly and Innovent Biologics expand research collaboration to develop and commercialise up to three anti-PD-1 based bispecific antibodies for Cancer
  • 20 Mar 2015 Preclinical bi-specific monoclonal antibodies licensed to Eli Lilly outside of China for the treatment of Cancer
  • 20 Mar 2015 Eli Lilly and Innovent agree to co-develop a preclinical bi-specific monoclonal antibody in China for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top